Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring
Joint Authors
Sharma, Munish
Mascarenhas, Daniel A. N.
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-01-26
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Ticagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS).
According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic and nonfatal to the patient.
We present a case of ticagrelor related second-degree type II heart block causing severe dizziness and diaphoresis that resolved after discontinuation of the medication.
American Psychological Association (APA)
Sharma, Munish& Mascarenhas, Daniel A. N.. 2017. Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring. Case Reports in Cardiology،Vol. 2017, no. 2017, pp.1-4.
https://search.emarefa.net/detail/BIM-1144070
Modern Language Association (MLA)
Sharma, Munish& Mascarenhas, Daniel A. N.. Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring. Case Reports in Cardiology No. 2017 (2017), pp.1-4.
https://search.emarefa.net/detail/BIM-1144070
American Medical Association (AMA)
Sharma, Munish& Mascarenhas, Daniel A. N.. Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring. Case Reports in Cardiology. 2017. Vol. 2017, no. 2017, pp.1-4.
https://search.emarefa.net/detail/BIM-1144070
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1144070
